The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis

被引:46
|
作者
Alicino, Cristiano [1 ]
Paganino, Chiara [1 ]
Orsi, Andrea [1 ]
Astengo, Matteo [1 ]
Trucchi, Cecilia [1 ]
Icardi, Giancarlo [1 ]
Ansaldi, Filippo [1 ]
机构
[1] Univ Genoa, Dept Hlth Sci, Via Pastore 1, I-16132 Genoa, Italy
关键词
Pneumonia; CAP; Streptococcus pneumoniae; Hospitalization; Prevention; Vaccines; PCV10; PCV13; Meta-analysis; NONTYPABLE HAEMOPHILUS-INFLUENZAE; COMMUNITY-ACQUIRED PNEUMONIA; CHILDHOOD PNEUMONIA; ECONOMIC-IMPACT; PUBLIC-HEALTH; PHID-CV; STREPTOCOCCUS-PNEUMONIAE; SEQUENTIAL INTRODUCTION; VACCINATION SCHEDULE; DISEASE;
D O I
10.1016/j.vaccine.2017.09.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: This systematic review and meta-analysis aimed at summarizing available data on the impact of PCV10 and PCV13 in reducing the incidence of CAP hospitalizations in children aged <5 years. Methods: A systematic search of the literature was conducted. We included time-series analyses and before-after studies, reporting the incidence of hospitalization for pneumonia in the periods before and after the introduction of PCV10 or PCV13 into the immunization program. Pooled estimates of Incidence Rate Ratio (IRR) were calculated by using a random-effects meta-analytic model. Results were stratified according to age-groups (<24 months and 24-59 months) and case definitions of pneumonia (clinically and radiologically confirmed pneumonia). Results: A total of 1533 potentially relevant articles were identified. Of these, 12 articles were included in the analysis. In children aged <24 months, the meta-analysis showed a reduction of 17% (95%CI: 11-22%, p-value < 0.001) an of 31% (95%CI: 26-35%, p-value < 0.001) in the hospitalization rates respectively for clinically and radiologically confirmed pneumonia, respectively, after the introduction of the novel PCVs. Results: In children aged 24-59 months, the meta-analysis showed a reduction of 9% (95%CI: 5-14%, p-value < 0.001) and of 24% (95%CI: 12-33%, p-value < 0.001) in the hospitalization rates for clinically and radiologically confirmed pneumonia, respectively, after the introduction of the novel PCVs. Results: High heterogeneity was detected among studies evaluating the hospitalization rate for clinically and radiologically confirmed pneumonia. Conclusions: The results of this study revealed a significant impact of PCV10 and PCV13 in reducing the hospitalizations for pneumonia, particularly in children aged <24 months and for radiologically confirmed disease. Further appropriately designed studies, comparing the impact of PCV10 and PCV13, are needed in order to obtain solid data on which to establish future immunization strategies. (C) 2017 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:5776 / 5785
页数:10
相关论文
共 50 条
  • [1] Pneumococcal immunization with conjugate vaccines: are 10-valent and 13-valent vaccines similar?
    Esposito, Susanna
    Principi, Nicola
    [J]. FUTURE MICROBIOLOGY, 2019, 14 (11) : 921 - 923
  • [2] Pneumococcal immunization with conjugate vaccines - are 10-valent and 13-valent vaccines similar?
    Vyse, Andrew
    Theilacker, Christian
    Sings, Heather
    Fletcher, Mark
    [J]. FUTURE MICROBIOLOGY, 2020, 15 (08) : 575 - 578
  • [3] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease
    Theilacker, Christian
    Hilton, Betsy
    Jiang, Qin
    Gessner, Bradford D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1641 - 1642
  • [4] Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data
    Feng, Shuo
    McLellan, Julie
    Pidduck, Nicola
    Roberts, Nia
    Higgins, Julian P. T.
    Choi, Yoon
    Izu, Alane
    Jit, Mark
    Madhi, Shabir A.
    Mulholland, Kim
    Pollard, Andrew J.
    Temple, Beth
    Voysey, Merryn
    [J]. ECLINICALMEDICINE, 2023, 61
  • [5] Comparing the Impact of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease Reply
    Naucler, Pontus
    Galanis, Ilias
    Morfeldt, Eva
    Darenberg, Jessica
    Ortqvist, Ake
    Henriques-Normark, Birgitta
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 66 (10) : 1642 - 1643
  • [6] The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease
    Principi, Nicola
    Esposito, Susanna
    [J]. EXPERT REVIEW OF VACCINES, 2015, 14 (10) : 1359 - 1366
  • [7] Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis
    Vadlamudi, Nirma Khatri
    Chen, Anna
    Marra, Fawziah
    [J]. CLINICAL INFECTIOUS DISEASES, 2019, 69 (01) : 34 - 49
  • [8] Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
    Hanquet, Germaine
    Krizova, Pavla
    Dalby, Tina
    Ladhani, Shamez N.
    Nuorti, J. Pekka
    Danis, Kostas
    Mereckiene, Jolita
    Knol, Mirjam J.
    Winje, Brita A.
    Ciruela, Pilar
    de Miguel, Sara
    Eugenia Portillo, Maria
    MacDonald, Laura
    Morfeldt, Eva
    Kozakova, Jana
    Valentiner-Branth, Palle
    Fry, Norman K.
    Rinta-Kokko, Hanna
    Varon, Emmanuelle
    Corcoran, Mary
    van der Ende, Arie
    Vestrheim, Didrik F.
    Munoz-Almagro, Carmen
    Sanz, Juan-Carlos
    Castilla, Jesus
    Smith, Andrew
    Henriques-Normark, Birgitta
    Colzani, Edoardo
    Pastore-Celentano, Lucia
    Savulescu, Camelia
    [J]. EMERGING INFECTIOUS DISEASES, 2022, 28 (01) : 127 - 138
  • [9] Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia
    Urbancikova, Ingrid
    Prymula, Roman
    Goldblatt, David
    Roalfe, Lucy
    Prymulova, Karolina
    Kosina, Pavel
    [J]. VACCINE, 2017, 35 (38) : 5186 - 5193
  • [10] A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A428 - A428